Gilead Sciences (GILD)
$67.08 0.15 (0.22%)
16:51 EST GILD Stock Quote Delayed 15 Minutes
Previous Close $66.93
Market Cap 87.22B
PE Ratio 25.51
Volume (Avg. Vol.) 4.27M
Day's Range 66.13 - 67.18
52-Week Range 60.32 - 70.50
Dividend & Yield 2.23 (3.32%)
GILD Stock Predictions, Articles, and Gilead Sciences News
- From InvestorPlace
- From the Web
The stock charts of GILD, DISH and MCK are put under the trading microscope as the next great trading prospects.
Gilead Sciences, Pfizer, Tesla, Netflx and Facebook are our top stock trades for Tuesday. Here's a look at the charts.
This morning, I am recommending a bullish trade on Gilead Sciences, Inc. (NASDAQ:GILD), the biopharmaceutical company.
If you're looking for good stocks to buy, here are seven ideas from one of America's best public pension plans.
Gilead has been dead money for some time and with good reason. Still, it seems that much of the bad news is baked into GILD stock.
Wells Fargo, HP and Gilead Sciences are just three oversold stocks to sell before they lose any more ground.
Tesla, Gilead, Twitter, The Trade Desk and Realty Income are our top stock trades to watching going into Tuesday morning's trading session.
The markets punished GILD stock for the underlying company’s poor Q4 results, but they’re ignoring GILD's bigger picture.
Gilead stock has been stagnating, but there are other choices for investors. How about considering Celgene over GILD stock?
Corning, Netflix and Phillips 66 all have brewing breakouts, making them some of our must-see stock charts for Wednesday.
Gilead Sciences stock was on its way down Tuesday after releasing data from a recent Phase 3 clinical trial concerning its drug selonsertib.
Alphabet, Gilead Sciences and Estee Lauder all reported earnings. Starbucks and Boeing are breaking out. Here's our top stock trades.
Gilead Sciences earnings came in below what analysts projected, while revenue beat expectations, but GILD stock declined after hours Monday.
If you're looking for bargains, top analysts believe these cheap stocks are a great place to start. Here's what to know.
These three biopharma stocks to buy should help investors maintain strength amid any potential chaos in 2019.
Healthcare stocks have not avoided the malady that has been dragging the markets down. Here are five that are currently looking rough.
Navellier RatingsPowered by Portfolio Grader